Kathryn J. Gregory

Avillion names new Chief Business Officer

Late-stage pharmaceuticals financing and co-development specialist Avillion LLP has named Kathryn J. Gregory Chief Business Officer.

Gregory, who will work from the US to expand clinical co-development opportunities for London-based Avillion, joins Avillion from Seneb BioSciences, an early-stage orphan drug developer. She brings in over 25 years of executive leadership experience in business development of biotechnology and pharmaceutical companies. At Purdue Pharma where she was responsible for business development transactions, identification, evaluation and negotiation of new business development opportunities and collaborations. Prior to Purdue, Gregory worked at Shire Pharmaceuticals and led business development transactions for the Neuroscience and Ophthalmology Business Units. Earlier in her career, Ms Gregory was Vice President, Business Development for PhaseBio Pharmaceuticals, and was Head of North America Sourcing and Procurement at Teva Pharmaceuticals